On 13 November 2025, Hong Kong Economic Journal (HKEJ), Hong Kong’s first Chinese-language financial newspaper, hosted the “ESG & Sustainability Awards of Excellence 2025” ceremony. At the event, Fosun International received the “ESG & Corporate Sustainability Excellence Award”, recognizing its remarkable achievements and strong market standing in advancing environmental, social, and governance (ESG) practices as well as sustainability.

SHANGHAI, China – NOVEMBER 11, 2025 – Shanghai Henlius Biotech, Inc. (2696.HK) today announced the Medicines and Healthcare Products Regulatory Agency (MHRA) in the United Kingdom has granted marketing authorization for BILDYOS^® (denosumab) injection 60 mg/mL and BILPREVDA^® (denosumab) injection 120 mg/1.7 mL, biosimilars to PROLIA (denosumab) and XGEVA (denosumab), respectively, for all indications of the reference products.

On 8 November, Guo Guangchang, Chairman of Fosun International, attended the 3rd Pujiang Biopharmaceutical Original Innovation Conference 2025. During the conference, Guo Guangchang stated, “At this crucial juncture today, China’s pharmaceutical innovation is gaining increasing attention and recognition around the world. More than ever, we are convinced that original innovation is the only way forward for the industry, and open cooperation is the best way to accelerate innovation.”

On the evening of 6 November 2025, The Asset, a renowned Asian financial magazine, hosted “The Asset Corporate Sustainability Leadership Awards 2025” ceremony in Singapore. Fosun International Limited (“Fosun International” or the “Company”) (HKEX stock code: 00656) was awarded “The Asset Corporate Sustainability Leadership Awards 2025 – Gold Award” and the “Best Sustainability Team”.

On 5 November 2025, the 8th China International Import Expo (CIIE) opened at the National Exhibition and Convention Center (Shanghai). As a “full-attendance” exhibitor for eight consecutive years, Fosun, together with its overseas member companies and global partners, is showcasing a range of world-leading innovative drugs, advanced medical devices, and achievements in international collaboration at the Fosun Pharma booth in the Medical Equipment and Healthcare Products Exhibition Area. The exhibits focus on core therapeutic areas including oncology, immune-inflammatory disorders, central nervous system, and kidney diseases, highlighting holistic breakthroughs in medical technology, from diagnosis and treatment to recovery.

On October 30, 2025, the First International Jewelry Fashion Theme Month and the 2025 Shanghai Haute Couture Week officially kicked off in the Grand Yuyuan Cultural Area. As the first major event following the establishment of the Shanghai International Jewelry & Style District, this inaugural theme month not only brings a series of exciting activities but also marks a new chapter in the development of the functional district.

Hong Kong, October 28, 2025 -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the "Group"), a global consumer wellness group offering Energy-Based Devices (EBD), injectables, and other complementary solutions, today announced its business update for the third quarter of 2025, highlighting solid revenue growth and accelerated momentum across core product segments and key markets.

(October 28, 2025, Shanghai, China)– On October 28, 2025, Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (“Fosun Pharma” or “the Group”; SSE: 600196, HKEX: 02196), a leading innovation-driven global healthcare company, announced its financial results for the first three quarters of 2025.

Recently, during the 63rd Annual Meeting of the Japan Society of Clinical Oncology (JSCO), Henlius successfully hosted the “Bridging Horizons · Henlius Japan Reception 2025” expert exchange symposium in Yokohama, Japan.